Randomized controlled trial shows significant increases in appetite and anthropometric measures in underweight adults, indicating potential for innovative nutritional strategies.
Undernutrition in adults increases mortality and impairs immunity and quality of life. Gut microbiota influences metabolism, suggesting potential for probiotic-based weight-gain strategies. This study aimed to assess the efficacy of a probiotic supplement combined with a weight-gain diet on anthropometric indices, appetite, and calorie intake in underweight adults. In this 8-week, double-blind, randomized, placebo-controlled trial, 95 underweight adults (aged 18-60 years) from Mashhad, Iran, were randomized to receive a probiotic supplement (Lacticaseibacillus rhamnosus GG, Lactobacillus acidophilus, Lacticaseibacillus casei; 109 CFU/capsule) or placebo with a 500-kcal surplus diet. Primary outcomes included anthropometric measures, including body weight and BMI. Secondary outcomes included appetite (via visual analog scales), caloric intake, and stool consistency. The probiotic group (n = 47) showed greater increases than the placebo group (n = 48) in body weight (2.41 vs 0.44 kg, p < 0.001), BMI (0.83 vs 0.24 kg/m², p < 0.001), body fat percentage (3.23% vs 1.03%, p < 0.001), fat mass (1.90 vs 0.89 kg, p = 0.002), and caloric intake (263.55 vs 30.75 kcal/day, p < 0.001). The probiotic group showed significant increases in hunger (p < 0.001) and desire to eat (p < 0.001), with reduced satiety and fullness before meals (p < 0.001), as assessed by VAS. Stool consistency in the probiotic group shifted significantly toward softer, more regular stools, as evidenced by a one-unit increase in the Bristol Stool Score (p = 0.01), compared to no change in the control group (p = 0.97). Probiotic supplementation with a weight-gain diet significantly enhances anthropometric measures, appetite, and calorie intake in underweight adults, offering a novel strategy for managing undernutrition. Clinical trial registration: Iranian Registry of Clinical Trials, IRCT20230310057667N1 (Issue date 30 March 2023), https://irct.behdasht.gov.ir/trial/69130.
No takes yet. Share an insight, caveat, or question.
Hatami et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: